These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 27128817)

  • 1. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
    Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
    Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
    Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
    Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis.
    Remuzgo-Martínez S; Genre F; López-Mejías R; Ubilla B; Mijares V; Pina T; Corrales A; Blanco R; Martín J; Llorca J; González-Gay MA
    Sci Rep; 2016 Jul; 6():29713. PubMed ID: 27403809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
    Vitovski S; Phillips JS; Sayers J; Croucher PI
    J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.
    Audo R; Daien C; Papon L; Lukas C; Vittecoq O; Hahne M; Combe B; Morel J
    Arthritis Res Ther; 2015 Jul; 17(1):193. PubMed ID: 26220665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin, trail and osteoprotegerin/trail ratio in patients at early phase of acute pancreatitis.
    Dumnicka P; Zylka A; Kusnierz-Cabala B; Gurda-Duda A; Kuzniewski M; Drozdz R; Kulig J
    Folia Med Cracov; 2014; 54(2):17-26. PubMed ID: 25648306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.
    Van Poznak C; Cross SS; Saggese M; Hudis C; Panageas KS; Norton L; Coleman RE; Holen I
    J Clin Pathol; 2006 Jan; 59(1):56-63. PubMed ID: 16394281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/RANKL/TRAIL and Wnt inhibitors.
    Taylan A; Birlik M; Kenar G; Toprak B; Gundogdu B; Gurler O; Karakas B; Akıncı B; Sisman AR
    Mod Rheumatol; 2019 Jul; 29(4):619-624. PubMed ID: 30001654
    [No Abstract]   [Full Text] [Related]  

  • 9. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
    Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
    Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients].
    Shiota J; Izumi N; Kasahara H; Tagawa H; Chiba T; Nihei H
    Nihon Jinzo Gakkai Shi; 2010; 52(8):1022-8. PubMed ID: 21254698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction.
    Pepene CE; Ilie IR; Marian I; Duncea I
    Eur J Endocrinol; 2011 Jan; 164(1):61-8. PubMed ID: 20974706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
    Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
    Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.
    Matsubara K; Stenvinkel P; Qureshi AR; Carrero JJ; Axelsson J; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Suliman ME
    J Nephrol; 2009; 22(6):774-82. PubMed ID: 19967657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men.
    Gibellini D; Borderi M; De Crignis E; Cicola R; Vescini F; Caudarella R; Chiodo F; Re MC
    J Med Virol; 2007 Oct; 79(10):1446-54. PubMed ID: 17705184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of exercise on osteoprotegerin and TNF-related apoptosis-inducing ligand in obese patients.
    Davenport C; Kenny H; Ashley DT; O'Sullivan EP; Smith D; O'Gorman DJ
    Eur J Clin Invest; 2012 Nov; 42(11):1173-9. PubMed ID: 22803952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between aortic pulse wave velocity, selected proinflammatory cytokines, and vascular calcification parameters in peritoneal dialysis patients.
    Krzanowski M; Janda K; Dumnicka P; Dubiel M; Stompór M; Kuśnierz-Cabala B; Grodzicki T; Sułowicz W
    J Hypertens; 2014 Jan; 32(1):142-8. PubMed ID: 24309487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy.
    Abu El-Asrar AM; Ahmad A; Alam K; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
    Ocul Immunol Inflamm; 2018; 26(8):1248-1260. PubMed ID: 28914577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity.
    Venuraju SM; Yerramasu A; Corder R; Lahiri A
    J Am Coll Cardiol; 2010 May; 55(19):2049-61. PubMed ID: 20447527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
    Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
    Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.